Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes
Michael A Via1, Himani Chandra2, Takako Araki1, Matthew V Potenza3, Maria Skamagas41Division of Endocrinology and Metabolism, Albert Einstein College of Medicine, Beth Israel Medical Center, New York, NY, USA; 2Division of Endocrinology, Diabetes and Bone Disease, Mount Sinai School of Medicine, Jam...
Saved in:
| Main Author: | Via MA |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Dove Medical Press
2010
|
| Subjects: | |
| Online Access: | https://doaj.org/article/cb1201f357514f8c890611a7afef052d |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes
by: Michael A Via, et al.
Published: (2010) -
The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis
by: Yunzhi Zou, et al.
Published: (2021) -
Glycemic control and diabetes complications among diabetes mellitus patients attending at University of Gondar Hospital, Northwest Ethiopia
by: Fasil A, et al.
Published: (2018) -
Poor Glycemic Control and Its Contributing Factors Among Type 2 Diabetes Patients at Adama Hospital Medical College in East Ethiopia
by: Yosef T, et al.
Published: (2021) -
Glycemic Control, Diabetes Complications and Their Determinants Among Ambulatory Diabetes Mellitus Patients in Southwest Ethiopia: A Prospective Cross-Sectional Study
by: YimamAhmed M, et al.
Published: (2020)